文献速递头颈部肿瘤放疗

粒子束放射治疗鼻咽癌:系统综述与Meta分析

Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-08-23

该系统综述与Meta分析检索2007年1月1日至2021年11月3日PubMed、Scopus和Embase数据库,纳入26项研究共1502例原发或复发鼻咽癌患者,评估质子或碳离子束治疗的生存与毒性。原发患者1年、2年、3年、5年汇总总生存率分别为96%、93%、90%、73%,≥3级晚期毒性≤20%。作者认为粒子束治疗潜力大,但需进一步研究长期结局与成本效益。

要点

  • 原发鼻咽癌粒子束治疗后1年、2年、3年、5年汇总总生存率分别为96%、93%、90%、73%。
  • 原发患者1年和2年无进展生存率及局部控制率均超过90%。
  • 复发患者1年总生存率65%~92%,1年局部控制率80%~88%,约5%报告死亡。

核心结论

  • 该系统综述与Meta分析显示粒子束治疗鼻咽癌潜力大,生存结局优异且毒性低,但需进一步研究评估长期结局与成本效益。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus和Embase数据库2007年1月1日至2021年11月3日文献,纳入26项研究共1502例原发或复发鼻咽癌患者,干预为质子或碳离子束治疗,样本量≥10例。
  • 采用随机效应Meta分析评估原发鼻咽癌患者,对复发患者结果进行定性描述。

主要发现

  • 原发鼻咽癌患者粒子束治疗后1年、2年、3年、5年汇总总生存率分别为96%(95%CI=92%-98%)、93%(95%CI=83%-97%)、90%(95%CI=73%-97%)、73%(95%CI=52%-87%)。
  • 原发鼻咽癌患者1年和2年汇总无进展生存率及局部控制率均超过90%。
  • 局部复发鼻咽癌患者1年总生存率范围为65%至92%,1年局部控制率范围为80%至88%。
  • 原发和复发患者中质子与碳离子束治疗总体安全,≥3级晚期毒性发生率≤20%。
  • 复发患者中报告约5%的死亡率。

局限性

  • 原文指出需进一步研究评估该新型放疗的长期结局与成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: A systematic review and meta-analysis were performed to better understand the benefits of particle beam therapy for nasopharyngeal cancer (NPC) treatment. The survival outcomes and toxicity of primary and recurrent NPC patients treated with proton or carbon ion beam therapy were investigated. METHOD: PubMed, Scopus, and Embase were searched between 1 January 2007 to 3 November 2021. The inclusion and exclusion criteria included studies with either primary or recurrent NPC patients, sample size of ≥10 patients, and proton or carbon ion beam therapy as interventions. Twenty-six eligible studies with a total of 1502 patients were included. We used a random-effect meta-analysis to examine the impact of particle beam therapy on primary NPC patients and qualitatively described the results among recurrent patients. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), local control (LC) and toxicity. RESULTS: The pooled OS at 1-year, 2-year and 3-year and 5-year for primary NPC patients who received particle beam therapy were 96 % (95 % confidence interval (CI) = 92 %-98 %), 93 % (95 % CI = 83 %-97 %), 90 % (95 % CI = 73 %-97 %) and 73 % (95 % CI = 52 %-87 %) respectively. The pooled 1-year and 2-year PFS, and LC for these patients were above 90 %. For locally recurrent NPC patients, the 1-year OS rate ranged from 65 % to 92 %, while the 1-year LC rate ranged from 80 % to 88 %. Both proton and carbon ion beam therapy were generally safe among primary and recurrent patients, with ≥G3 late toxicity rates of 20 % or less. Approximately a 5 % mortality rate was reported among recurrent patients. CONCLUSIONS: This systematic review and meta-analysis demonstrated particle beam therapy has great potential in treating NPC, yielding excellent survival outcomes with low toxicity. However, further investigations are needed to assess the long-term outcomes and cost-effectiveness of this newer form of radiotherapy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ng WT, But B, Wong CHL, et al. Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022. PMID: 36065359. doi:10.1016/j.ctro.2022.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。